PFSCF News Alert Prometic Life Scienc (PFSCF) 1.5155 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Prometic Life Scienc (PFSCF) 1.5155 $PFSCF

ProMetic to Be Added to S&P/TSX SmallCap Index
Marketwire - Tue Sep 16, 6:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it will be added to the S&P/TSX SmallCap Index ("Index" , effective after the close of trading on Friday, September 19, 2014, as the result of the annual review of the Index.

Chemotherapy Induced Anemia Therapeutics Pipeline Review 2014 - 9 Companies & 11 Drug Profiles
M2 - Wed Sep 10, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqbww2/chemotherapy) has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - 3SBio Inc. - ProMetic Life Sciences Inc. - Avesthagen Limited - Therapure Biopharma Inc. - Tarix Pharmaceuticals LTD. - Aprogen, Inc. - Tolero Pharmaceuticals, Inc. - SBI Pharmaceuticals Co., Ltd. Drug Profiles - epoetin alfa - PBI-1402 - LY-2787106 - aminolevulinic acid hydrochloride - NuPIAO - darbepoetin alfa - PanCyte - PBI-4494 - TBI-304 - darbepoetin alfa - TP-0413 For more information visit http://www.researchandmarkets.com/research/tq...emotherapy

Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ProMetic Reports Successful PBI-4050 Pre-IND Meeting with the FDA
Marketwire - Wed Sep 03, 5:31AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" announced today it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA" for its anti-fibrotic, lead drug candidate, PBI-4050.

ProMetic Reports its Second Quarter 2014 Highlights and Financial Results
Marketwire - Thu Aug 14, 3:02PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported revenues of $4.4 million and a net profit of $23.4 million for the second quarter ended June 30, 2014 resulting from the recognition of a gain on revaluation of the equity investment of ProMetic's equity interest in NantPro.

ProMetic to Report its Second Quarter 2014 Financial Results and Hold Conference Call / Webcast
Marketwire - Mon Aug 11, 11:35AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today announced that it will report its financial results for the second quarter ended June 30, 2014 on Thursday August 14, 2014 after market hours.

ProMetic Secures $20 Million Follow-on Investment from Thomvest Seed Capital Inc.
Marketwire - Fri Aug 01, 7:18AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it has secured a follow-on investment from Thomvest Seed Capital Inc. ("Thomvest" , the Toronto-based investment vehicle of Peter J. Thomson, consisting of a $20 million Loan. As partial consideration for the Loan, ProMetic has granted Thomvest 16,723,807 warrants with an exercise price of $1.87 per common share, a premium of 52% to yesterday's closing share price.

ProMetic Enters Into New Product Program With an Existing Multinational Client
Marketwire - Thu Jul 24, 7:40AM CDT
July 24, 2014 - ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" announced today the signing of an agreement (the "Agreement" by ProMetic's UK subsidiary, ProMetic Biosciences Ltd ("PBL" , with one of its existing multinational clients, a global leader in the biotherapeutics industry.

ProMetic to Commercially Launch Fibrinogen in the Fourth Quarter of 2014
Marketwire - Thu Jul 10, 7:09AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" announced today that it will launch fibrinogen for commercial sales during the fourth quarter of 2014 after its successful scale-up at its Laval based plasma purification facility, ProMetic BioProduction Inc. ("PBP" . This follows the previously disclosed proteins already scheduled for production at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin.

ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial
Marketwire - Wed Jun 18, 5:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation" reported today that it has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers. ProMetic's PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested.

ProMetic Reports Successful Pre-IND Meeting with the FDA
Marketwire - Wed Apr 02, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA" for a plasma-derived biopharmaceutical currently under development under the NantPro, LLC joint venture.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 111

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 170

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 103

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 161

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 61

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 120

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading

Top 5 Most Recently Viewed Articles

Gap Inc. Sees Minor Sales Growth Amid Market Challenges

Updated Category News Views 254

Gap Inc. Experiences Modest Growth Gap Inc. demonstrated resilience in a challenging market, achieving a 1% increase in net sales compared to the previous year. The comparable sales rose by 3%, reflecting the brand's enhancement strategies. Brand Performance Highlight Each of Gap Inc.'s four major brands—Old Navy, Gap, Banana Republic, and Athleta—gained market share,...

Continue Reading
Innovative Lock Design Enhances Security for Commercial Trailers

Updated Category News Views 761

The SMART LOC: A Game-Changer for Trucking Security In a world where cargo theft is a persistent challenge, the development of an innovative solution is essential. Enter the SMART LOC, a new locking mechanism designed specifically for commercial trailers. This invention aims to significantly enhance security for trucking professionals, ultimately providing much-needed...

Continue Reading
GXO Logistics Prepares for First Quarter Earnings Call Soon

Updated Category News Views 198

GXO Logistics Set for First Quarter Earnings Presentation GXO Logistics, Inc. (NYSE: GXO) is preparing for its first quarter earnings conference call, which is scheduled for May 8, 2025, at 8:30 a.m. Eastern Time. During this call, the company will share its financial results and key insights into its business performance. Interested participants are encouraged to join in...

Continue Reading
Legal Action Against Everus Construction Group for Investors

Updated Category News Views 132

Overview of Legal Proceedings Against Everus Construction Group Everus Construction Group, Inc. (NYSE: ECG) is currently facing significant legal challenges as a result of alleged securities law violations. The situation has prompted attention from shareholders and investors alike. The Gross Law Firm has taken the initiative to notify shareholders regarding this serious...

Continue Reading
Nxera Pharma and Cancer Research UK Collaborate to Combat Cancer

Updated Category News Views 121

Nxera Pharma Joins Forces with Cancer Research UK for Innovative Trials HTL0039732, a promising oral EP4 antagonist developed by Nxera, shows potential in tackling various types of cancer, especially when paired with leading immunotherapies. Currently, this drug is making progress through its Phase 1/2a clinical trials, highlighting its potential effectiveness across a...

Continue Reading